Panel Discussion: Applying GFR Slope & Hierarchical Composite Endpoints to Capture More Patient Data & Increase Trial Efficiency, & Exploring Kidney Health Markers Beyond
12:00 pm - Wednesday 17th March 2027
- Determining where GFR slope is sufficiently robust to act as a primary endpoint
- Incorporating cardiovascular events, quality of life and additional components into hierarchical composites
- Evaluating whether these approaches can reduce sample size or required follow-up without weakening evidence
- The potential of the kidney HCE in specific kidney diseases: examples from FSGS and ADPKD
Speakers:
Senior Vice President - Clinical Development, Medical Lead - Complement Therapeutics
Nuvectis Pharma